Alkermes plc (NASDAQ: ALKS) presented detailed results from its Vibrance-2 phase 2 study of alixorexton in adults with narcolepsy type ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE